Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could vitamin d levels predict nerve damage in diabetes?

NCT ID NCT07236723

Knowledge-focused Sponsor: Aswan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will measure vitamin D and nerve growth factor levels in 57 men with type 2 diabetes and nerve damage, comparing them to diabetic men without nerve damage and healthy men. Researchers will also test nerve function using electrical studies. The goal is to see if low vitamin D or nerve growth factor is linked to worse nerve damage, which could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward vitamin D or nerve growth factor as targets for future treatments for diabetic neuropathy.
What could go wrong
This is a small observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to women or other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 57 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Group І: Control group included non-diabetic healthy males. Group П: Type 2 male diabetic patients not suffering from diabetic neuropathy in Aswan University Hospital of matched age. Group III: Type 2 male diabetic patients suffering from diabetic neuropathy in Aswan University Hospital of matched age.

Ages

40 to 60 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult male patients 40 -65 years' old who have type 2 diabetes mellitus on oral hypoglycemic , non-diabetic healthy subjects of matched age and type 2male diabetic neuropathy patients of matched age . Exclusion Criteria: * Cardiac patients. * Patients who have transient ischemic attack or stroke. * Patients with inflammatory rheumatic diseases. * Patients with malignant diseases. * Hyperparathyroidism. * Hypothyroidism. * Renal impairment with renal replacement therapy. * Liver diseases. * Patients on vitamin D supplementation. * Patients on vitamin B12 supplementation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic neuropathy hereditary sensory and autonomic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aswan university hospital

    Aswān, Aswan Governorate, 81157, Egypt

  • Aswan university hospital

    Aswān, Aswan Governorate, Aswan, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.